Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2026
Real world performance of once weekly somatrogon on naive patients with isolated growth hormone deficiency: Mind the weight gain.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Moutafi Maria, Sotiriou Georgia, Triantafyllou Panagiota, Papagianni Maria, Christoforidis Athanasios
Аннотация
BACKGROUND: Growth hormone deficiency (GHD) is a common cause of short stature in children, associated with impaired growth and psychosocial challenges. Long-acting growth hormone (LAGH) formulations may reduce treatment burden compared with daily recombinant human GH (rhGH), but real-world evidence in treatment-naïve children with LAGH is still limited.
METHODS: We conducted a retrospective observational study including 30 treatment-naïve children with isolated GHD at a tertiary hospital in Greece. Fifteen children initiated somatrogon and 15 received daily rhGH. Patients were evaluated at baseline and at 6, 12 and 18 months for anthropometric parameters and serum IGF-1 values.
RESULTS: Height z-score improved over time in both groups, with no significant differences between weekly and daily therapy at any time point. BMI z-score increased significantly during the first 6 months in the weekly GH group and remained higher at 12 months, whereas no sustained differences were observed in the daily GH group. Serum IGF-1 Z-score increased over time in both groups, though the difference was not statistically significant. No patients discontinued therapy due to adverse events.
CONCLUSION: Somatrogon was effective and well tolerated in treatment-naïve children with GHD, providing sustained growth improvement and a potential advantage for adherence due to reduced injection frequency. However, increased body weight gain shown in the weekly GH group raises concerns and needs further confirmation and justification.
METHODS: We conducted a retrospective observational study including 30 treatment-naïve children with isolated GHD at a tertiary hospital in Greece. Fifteen children initiated somatrogon and 15 received daily rhGH. Patients were evaluated at baseline and at 6, 12 and 18 months for anthropometric parameters and serum IGF-1 values.
RESULTS: Height z-score improved over time in both groups, with no significant differences between weekly and daily therapy at any time point. BMI z-score increased significantly during the first 6 months in the weekly GH group and remained higher at 12 months, whereas no sustained differences were observed in the daily GH group. Serum IGF-1 Z-score increased over time in both groups, though the difference was not statistically significant. No patients discontinued therapy due to adverse events.
CONCLUSION: Somatrogon was effective and well tolerated in treatment-naïve children with GHD, providing sustained growth improvement and a potential advantage for adherence due to reduced injection frequency. However, increased body weight gain shown in the weekly GH group raises concerns and needs further confirmation and justification.